A New Adjuvant Regimen for Patients with Early Breast Cancer: Interim Results

The duration and composition of adjuvant endocrine therapy continue to evolve, particularly for breast cancer patients whose disease is at high risk for recurrence. Progress has been made, especially with the addition of CDK4/6 inhibitors for patients with estrogen receptor–positive (ER+), HER2−, metastatic breast cancer. However, results in patients with early-stage breast cancer (EBC) have been less consistent, although adding abemaciclib to endocrine therapy for 2 years has significantly improved invasive disease–free survival (iDFS) in patients with nodal involvement. Researchers now report prespecified interim results with ribociclib in NATALEE, an open-label, randomized, manufacturer-sponsored, phase 3 trial involving 5101 patients wi…